• Explore /
  • Poster
  • / A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma (SIDNEY).

A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma (SIDNEY).

Abstract Poster

Authors

null

Pier Luigi Zinzani

Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy

Pier Luigi Zinzani , Stephen M. Ansell , Francesc Bosch , Jonathan W. Friedberg , Jean pierre Marolleau , Luca Arcaini , Ramón Garcia-Sanz , Ajay K. Gopal , Carlos Grande , Reid Merryman , Antonio Pinto , Stephen D. Smith , Jose Caetano Villasboas , Danielle Wallace , Jan Fagerberg , Joao Magalhaes , Philippe Armand

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04669171

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS7586)

DOI

10.1200/JCO.2022.40.16_suppl.TPS7586

Abstract #

TPS7586

Poster Bd #

234b

Abstract Disclosures

Similar Posters

First Author: Umberto Vitolo

First Author: Eric Baudin

First Author: Laurie Helen Sehn

First Author: Adam J Olszewski